Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0EWRMR
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Site-sepcific ADC 4
|
|||||
| Synonyms |
Site-sepcific ADC 4
Click to Show/Hide
|
|||||
| Organization |
Shanghai Institute of Materia Medica, Chinese Academy of Sciences.; University of Chinese Academy of Sciences.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
0.71
|
|||||
| Structure |
|
|||||
| Antibody Name |
Zilovertamab
|
Antibody Info | ||||
| Antigen Name |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
TE-VC-PAB
|
Linker Info | ||||
| Conjugate Type |
Site-specific bioconjugation via NIR-II aza-BODIPY Platform
|
|||||